Kinetics of Prostate-Specific Antigen after Carbon Ion Radiotherapy for Prostate Cancer
Open Access
- 3 March 2020
- Vol. 12 (3), 589
- https://doi.org/10.3390/cancers12030589
Abstract
This study aimed to first elucidate prostate-specific antigen (PSA) kinetics in prostate cancer patients treated with carbon ion radiotherapy (CIRT). From 2010 to 2015, 131 patients with prostate adenocarcinoma treated with CIRT (57.6 Gy relative biological effectiveness (RBE) in 16 fractions) alone were recruited. PSA was measured at 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 months post-CIRT. PSA bounce was defined as PSA increase over a cutoff followed by spontaneous decrease to or below the pre-bounce nadir. PSA failure was determined using the Phoenix criteria (nadir + 2.0 ng/mL). As a result, non-failure-associated temporary increase in PSA exhibited two distinct patterns, namely a classical bounce and a surge at one month. PSA bounce of ≥0.2 ng/mL was observed in 55.7% of the patients. Bounce amplitude was <2.0 ng/mL in 97.6% of cases. Bounce occurred significantly earlier than PSA failure. Younger age was a significant predictor of bounce occurrence. Bounce positivity was a significant predictor of favorable 5-year PSA failure-free survival. Meanwhile, a PSA surge of ≥0.2 ng/mL was observed in 67.9% of patients. Surge amplitude was significantly larger than bounce amplitude. Larger prostate volume was a significant predictor of PSA surge occurrence. PSA surge positivity did not significantly predict PSA failure. In summary, PSA bounce was distinguishable from PSA failure with regard to timing of occurrence and amplitude (earlier and lower for bounce, respectively). These data are useful for post-CIRT surveillance of prostate cancer patients.This publication has 22 references indexed in Scilit:
- Radiotherapy and the Tumor Stroma: The Importance of Dose and FractionationFrontiers in Oncology, 2014
- Prostate-Specific Antigen Bounce Following Stereotactic Body Radiation Therapy for Prostate CancerFrontiers in Oncology, 2014
- Prostate-Specific Antigen Bounce After High-Dose-Rate Monotherapy for Prostate CancerInternational Journal of Radiation Oncology*Biology*Physics, 2013
- Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrenceRadiation Oncology, 2012
- PSA Bounce and Biochemical Failure After Brachytherapy for Prostate Cancer: A Study of 820 Patients With a Minimum of 3 Years of Follow-UpInternational Journal of Radiation Oncology*Biology*Physics, 2011
- Prostate-specific Antigen Bounce After Prostate Brachytherapy: Review of a Confusing PhenomenonUrology, 2009
- Analysis of prostate-specific antigen bounce after I125 permanent seed implant for localised prostate cancerRadiotherapy and Oncology, 2008
- PSA Kinetics and PSA Bounce Following Permanent Seed Prostate BrachytherapyInternational Journal of Radiation Oncology*Biology*Physics, 2007
- Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus ConferenceInternational Journal of Radiation Oncology*Biology*Physics, 2006
- PSA bounces after neoadjuvant androgen deprivation and external beam radiation: Impact on definitions of failureInternational Journal of Radiation Oncology*Biology*Physics, 2005